Journal
EUROPEAN JOURNAL OF CANCER
Volume 177, Issue -, Pages 33-44Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.09.032
Keywords
Androgen receptor; Cabazitaxel; CTC; Metastasis; Prostate cancer; NGS
Categories
Ask authors/readers for more resources
This study aimed to investigate the clinical efficacy of cabazitaxel treatment in AR-V7 positive mCRPC patients and collect liquid biopsy samples for genomic profiling.
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. Design: We performed a prospective, multicenter, single arm phase II clinical trial (CABA-V7) in mCRPC patients previously treated with docetaxel and androgen deprivation therapy. Objective: In this trial, we investigated whether cabazitaxel treatment resulted in clinically mean-ingful PSA response rates in patients with positive CTC-based AR-V7 expression and collected liquid biopsies for genomic profiling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
